Filgrastim

Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count.[12] Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause.[12] It may also be used to increase white blood cells for gathering during leukapheresis.[12] It is given either by injection into a vein or under the skin.[12]

Not to be confused with granulocyte-macrophage colony-stimulating factor or epoetin alfa.

Filgrastim
Clinical data
Trade namesNeupogen, others
Biosimilarsfilgrastim-aafi, filgrastim-sndz, filgrastim-ayow, Accofil, Biograstim, Fraven Grastofil, Nivestim,[1] Nivestym,[2] Nypozi, [3] Ratiograstim, Releuko,[4] Tevagrastim, Zarxio,[5] Zarzio[6]
AHFS/Drugs.comMonograph
MedlinePlusa692033
License data
Pregnancy
category
Routes of
administration		Intraveneous, subcutaneous
Drug classHematopoietic agents
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • Human granulocyte colony stimulating factor
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard100.167.401
Chemical and physical data
FormulaC845H1343N223O243S9
Molar mass18802.90 g·mol−1

Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss.[12] Severe side effects include splenic rupture and allergic reactions.[12] It is unclear if use in pregnancy is safe for the baby.[12] Filgrastim is a recombinant-DNA form of the naturally occurring granulocyte colony-stimulating factor (G-CSF).[12] It works by stimulating the body to increase neutrophil production.[12]

Filgrastim was approved for medical use in the United States in 1991.[12] It is on the World Health Organization's List of Essential Medicines.[13][14] Filgrastim biosimilar medications are available.[12]

Medical uses

Filgrastim is used to treat neutropenia,[15] stimulating the bone marrow to increase production of neutrophils. Causes of neutropenia include chemotherapy and bone marrow transplantation.

Adverse effects

The most commonly observed adverse effect is mild bone pain after repeated administration,[16] and local skin reactions at the site of injection.[17][11] Other observed adverse effects include serious allergic reactions (including a rash over the whole body,[18] shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, and sweating), ruptured spleen (sometimes resulting in death),[19] alveolar hemorrhage, acute respiratory distress syndrome, and hemoptysis.[17] Severe sickle cell crises, in some cases resulting in death, have been associated with the use of filgrastim in patients with sickle cell disorders.[11]

Interactions

Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes; this should be considered when interpreting bone-imaging results.[11]

Mechanism of action

G-CSF is a colony stimulating factor which has been shown to have minimal direct in vivo or in vitro effects on the production of other haematopoietic cell types. Neupogen (filgrastim) is the name for recombinant methionyl human granulocyte colony stimulating factor (r-metHuG-CSF).[11]

Society and culture

Biosimilars
See also: Biosimilars

In 2015, Sandoz's filgrastim-sndz (trade name Zarxio), obtained the approval of the U.S. Food and Drug Administration (FDA) as a biosimilar.[5][20][21] This was the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), as part of the Affordable Care Act.[5] Zarxio was approved as a biosimilar, not as an interchangeable product, the FDA notes. And under the BPCI Act, only a biologic that has been approved as an "interchangeable" may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA said its approval of Zarxio is based on review of evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Zarxio is biosimilar to Neupogen.[21]

In 2018, filgrastim-aafi (trade name Nivestym) was approved for use in the United States.[22]

In September 2008, Ratiograstim, Tevagrastim, Biograstim, and Filgrastim ratiopharm were approved for use in the European Union.[23][24][25][26] Filgrastim ratiopharm was withdrawn in July 2011 and Biograstim was withdrawn in December 2016.

In February 2009, Filgrastim Hexal and Zarzio were approved for use in the European Union.[27][6]

In June 2010, Nivestim was approved for use in the European Union.[1]

In October 2013, Grastofil was approved for use in the European Union.[28]

In September 2014, Accofil was approved for use in the European Union.[29]

In 2016, Fraven was approved for use by Republic of Turkey ministry of health.[30]

Nivestym was approved for medical use in Canada in April 2020.[2]

In October 2021, Nypozi was approved for medical use in Canada.[3]

Economics

Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia depended upon the clinical situation and the financial model used to pay for treatment.[31] The longer-acting pegfilgrastim may in some cases be more cost-effective.[32] The introduction of biosimilars into the market resulted in a price reduction for the original, patent-protected product and increased use.[33]

References
  1. "Nivestim EPAR". European Medicines Agency (EMA). Retrieved 20 December 2019.
  2. "Summary Basis of Decision (SBD) for Nivestym". Health Canada. Retrieved 29 May 2022.
  3. "Summary Basis of Decision (SBD) for Nypozi". Health Canada. Retrieved 29 May 2022.
  4. "Releuko- filgrastim injection, solution". DailyMed. 11 March 2022. Retrieved 16 March 2022.
  5. "FDA approves first biosimilar product Zarxio". U.S. Food and Drug Administration (FDA) (Press release). 6 March 2015. Archived from the original on 11 December 2015. Retrieved 23 November 2015.
  6. "Zarzio EPAR". European Medicines Agency (EMA). Retrieved 20 December 2019.
  7. "Filgrastim Use During Pregnancy". Drugs.com. 13 September 2018. Retrieved 17 December 2019.
  8. "Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2021. Retrieved 1 March 2022.
  9. "Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 4 July 2019. Retrieved 20 December 2019.
  10. "Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Retrieved 20 December 2019.
  11. "Neupogen- filgrastim injection, solution". DailyMed. 15 November 2019. Retrieved 20 December 2019.
  12. "Filgrastim". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 December 2016.
  13. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  14. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  15. Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36–46. doi:10.3816/SCT.2005.n.023. PMID 18632435.
  16. Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management". Ann Pharmacother. 51 (9): 797–803. doi:10.1177/1060028017706373. PMID 28423916. S2CID 33032446.
  17. Neupogen "Neupogen: Patient Information Leaflet". Amgen. Archived from the original on 10 November 2013. Retrieved 24 June 2013.
  18. Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S (September 2009). "Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption". Br. J. Dermatol. 161 (3): 717–9. doi:10.1111/j.1365-2133.2009.09371.x. PMID 19614649. S2CID 2655192.
  19. Zimmer BM, Berdel WE, Ludwig WD, Notter M, Reufi B, Thiel E (March 1993). "Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies". Leuk. Res. 17 (3): 277–83. doi:10.1016/0145-2126(93)90012-a. PMID 8450676.
  20. "Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). 20 April 2015. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  21. Tavernise, Sabrina; Pollack, Andrew (6 March 2015). "F.D.A. Approves Zarxio, Its First Biosimilar Drug". The New York Times. Archived from the original on 23 October 2015. Retrieved 23 November 2015.
  22. "Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). 21 February 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  23. "Ratiograstim EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  24. "Tevagrastim EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  25. "Biograstim EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  26. "Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  27. "Filgrastim Hexal EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  28. "Grastofil EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  29. "Accofil EPAR". European Medicines Agency (EMA). Retrieved 2 April 2020.
  30. Arven ilaç, Türkiye’nin ilk biyobenzer ürününü üretti - Vatan Finans.
  31. Neymark, Niels (1998). Assessing the Economic Value of Anticancer Therapies. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research. Vol. 148. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 215–219. doi:10.1007/978-3-642-72123-6. ISBN 978-3-642-72123-6. OCLC 851760173. PMID 9670279. S2CID 34894897.
  32. Ellery, Tony (2012). Pharmaceutical lifecycle management : making the most of each and every brand. Hansen, Neal. Hoboken, N.J.: John Wiley & Sons. p. 214. ISBN 978-1-118-26679-3. OCLC 797824835.
  33. Cornes, Paul (9 April 2018). Biosimilars. Bennett, David. Abingdon. p. 54. ISBN 978-1-910797-67-9. OCLC 1064690227.

Further reading
  • Santoso B, van Boxtel CJ, Edwards RI, eds. (2001). Drug benefits and risks: international textbook of clinical pharmacology. New York: Wiley. ISBN 0-471-89927-5.
  • "Filgrastim". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.